90357-06-5 | Bicalutamide

Packsize	Purity	Availability	Price	Discounted Price
50mg	99%	in stock	$6.00	$4.00
100mg	99%	in stock	$8.00	$6.00
250mg	99%	in stock	$11.00	$8.00
1g	99%	in stock	$22.00	$16.00
5g	99%	in stock	$76.00	$53.00
25g	99%	in stock	$262.00	$184.00
100g	99%	in stock	$785.00	$549.00

Description

• Catalog Number: AH94142
• Chemical Name: Bicalutamide
• CAS Number: 90357-06-5
• Molecular Formula: C18H14F4N2O4S
• Molecular Weight: 430.3734
• MDL Number: MFCD00869971
• SMILES: N#Cc1ccc(cc1C(F)(F)F)NC(=O)C(CS(=O)(=O)c1ccc(cc1)F)(O)C

Computed Properties

• Complexity: 750
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 29
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 5
• Undefined Atom Stereocenter Count: 1
• XLogP3: 2.3

Literature

• The promotion on cell growth of androgen-dependent prostate cancer by antimony via mimicking androgen activity.

  Toxicology letters 20180515

• Assessment of endocrine disruption and oxidative potential of bisphenol-A, triclosan, nonylphenol, diethylhexyl phthalate, galaxolide, and carbamazepine, common contaminants of municipal biosolids.

  Toxicology in vitro : an international journal published in association with BIBRA 20180401

• Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.

  Chemico-biological interactions 20170925

• Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals.

  Chemical research in toxicology 20170515

• 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.

  Chemico-biological interactions 20161225

• TBECH, 1,2-dibromo-4-(1,2 dibromoethyl) cyclohexane, alters androgen receptor regulation in response to mutations associated with prostate cancer.

  Toxicology and applied pharmacology 20160915

• Sensitization of androgen refractory prostate cancer cells to anti-androgens through re-expression of epigenetically repressed androgen receptor - Synergistic action of quercetin and curcumin.

  Molecular and cellular endocrinology 20160815

• Development and pre-validation of an in vitro transactivation assay for detection of (anti)androgenic potential compounds using 22Rv1/MMTV cells.

  Reproductive toxicology (Elmsford, N.Y.) 20160401

• The brominated flame retardants TBP-AE and TBP-DBPE antagonize the chicken androgen receptor and act as potential endocrine disrupters in chicken LMH cells.

  Toxicology in vitro : an international journal published in association with BIBRA 20151201

• Androgen receptor functions as a negative transcriptional regulator of DEPTOR, mTOR inhibitor.

  The Journal of toxicological sciences 20151201

• Testotoxicosis: Report of Two Cases, One with a Novel Mutation in LHCGR Gene.

  Journal of clinical research in pediatric endocrinology 20150901

• Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells.

  Toxicology 20150703

• Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells.

  The Journal of biological chemistry 20150619

• Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.

  Toxicological sciences : an official journal of the Society of Toxicology 20150601

• Identification of a group of brominated flame retardants as novel androgen receptor antagonists and potential neuronal and endocrine disrupters.

  Environment international 20150101

• Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

  Nature 20140612

• Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20140120

• Targeting cell cycle and hormone receptor pathways in cancer.

  Oncogene 20131128

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Bisphenol A affects androgen receptor function via multiple mechanisms.

  Chemico-biological interactions 20130525

• Dehydroepiandrosterone post-transcriptionally modifies CYP1A2 induction involving androgen receptor.

  Chemico-biological interactions 20130525

• Endocrine disruptors fludioxonil and fenhexamid stimulate miR-21 expression in breast cancer cells.

  Toxicological sciences : an official journal of the Society of Toxicology 20130101

• Androgen signaling promotes translation of TMEFF2 in prostate cancer cells via phosphorylation of the α subunit of the translation initiation factor 2.

  PloS one 20130101

• Development and validation of a highly sensitive LC-MS/MS-ESI method for the determination of bicalutamide in mouse plasma: application to a pharmacokinetic study.

  Biomedical chromatography : BMC 20121201

• Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade.

  BJU international 20121101

• Exploring the cyclooxygenase 2 (COX2)/15d-Δ(12,14)PGJ(2) system in hamster Sertoli cells: regulation by FSH/testosterone and relevance to glucose uptake.

  General and comparative endocrinology 20121101

• 3,3'-Disubstituted bipolar biphenyls as inhibitors of nuclear receptor coactivator binding.

  Bioorganic & medicinal chemistry letters 20121101

• Images in clinical medicine. Gynecomastia induced by prostate-cancer treatment.

  The New England journal of medicine 20121011

• Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

  BJU international 20121001

• Editorial comment. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

  BJU international 20121001

• SGEF is overexpressed in prostate cancer and contributes to prostate cancer progression.

  Oncology reports 20121001

• Androgens regulate Hedgehog signalling and proliferation in androgen-dependent prostate cells.

  International journal of cancer 20120915

• Autophagy regulates lipolysis and cell survival through lipid droplet degradation in androgen-sensitive prostate cancer cells.

  The Prostate 20120915

• A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.

  Clinical genitourinary cancer 20120901

• A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.

  Investigational new drugs 20120801

• Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.

  International journal of radiation oncology, biology, physics 20120801

• Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer.

  Pharmaceutical research 20120801

• Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models.

  International journal of oncology 20120801

• [Prostate carcinoma with squamous differentiation after combination endocrine therapy: a case report].

  Hinyokika kiyo. Acta urologica Japonica 20120801

• Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120715

• A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.

  The Journal of biological chemistry 20120706

• Red ginseng and 20(S)-Rg3 control testosterone-induced prostate hyperplasia by deregulating androgen receptor signaling.

  Journal of natural medicines 20120701

• Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer.

  Cancer immunology, immunotherapy : CII 20120701

• Chemical castration and anti-androgens induce differential gene expression in prostate cancer.

  The Journal of pathology 20120701

• Antitumor agents 290. Design, synthesis, and biological evaluation of new LNCaP and PC-3 cytotoxic curcumin analogs conjugated with anti-androgens.

  Bioorganic & medicinal chemistry 20120701

• Effects of the anti-androgen, bicalutamide, in a reduced life-cycle study with the fathead minnow (Pimephales promelas).

  Aquatic toxicology (Amsterdam, Netherlands) 20120615

• Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.

  The Prostate 20120601

• Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling.

  Pharmaceutical research 20120601

• Androgen deprivation causes truncation of the C-terminal region of androgen receptor in human prostate cancer LNCaP cells.

  Cancer science 20120601

• The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.

  Japanese journal of clinical oncology 20120601

• P53 and the proteasome regulate androgen receptor activity.

  Cancer biology & therapy 20120501

• Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

  Cancer research 20120501

• Estrogen receptor-α and sex steroid hormones regulate Toll-like receptor-9 expression and invasive function in human breast cancer cells.

  Breast cancer research and treatment 20120401

• [Impact of androgen deprivation on the lipid profile and atherogenic risk in prostate cancer patients].

  Actas urologicas espanolas 20120401

• Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists.

  Bioorganic & medicinal chemistry 20120401

• Development and validation of stability-indicating HPLC and UPLC methods for the determination of bicalutamide.

  Journal of chromatographic science 20120401

• Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer.

  International journal of radiation oncology, biology, physics 20120315

• ARN-509: a novel antiandrogen for prostate cancer treatment.

  Cancer research 20120315

• DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: a feasibility study.

  Magnetic resonance in medicine 20120301

• Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.

  Chemical biology & drug design 20120301

• Methoxychalcone inhibitors of androgen receptor translocation and function.

  Bioorganic & medicinal chemistry letters 20120301

• Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.

  The Prostate 20120201

• A comparative assessment of α-lipoic acid N-phenylamides as non-steroidal androgen receptor antagonists both on and off gold nanoparticles.

  Bioorganic chemistry 20120201

• Synthesis and characterization of bicalutamide-loaded magnetic nanoparticles as anti-tumor drug carriers.

  Journal of nanoscience and nanotechnology 20120201

• Antiandrogenic, maspin induction, and antiprostate cancer activities of tanshinone IIA and its novel derivatives with modification in ring A.

  Journal of medicinal chemistry 20120126

• Galbanic acid decreases androgen receptor abundance and signaling and induces G1 arrest in prostate cancer cells.

  International journal of cancer 20120101

• Higher percentage of positive biopsy cores and Gleason score are associated with a greater degree of prostate gland shrinkage after neoadjuvant cytoreductive therapy.

  Brachytherapy 20120101

• Understanding the performance of melt-extruded poly(ethylene oxide)-bicalutamide solid dispersions: characterisation of microstructural properties using thermal, spectroscopic and drug release methods.

  Journal of pharmaceutical sciences 20120101

• Combined treatment with bicalutamide and anastrozole in a young boy with peripheral precocious puberty due to McCune-Albright Syndrome.

  Endocrine journal 20120101

• Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists.

  Bioorganic & medicinal chemistry 20120101

• Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer.

  World journal of surgical oncology 20120101

• The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation.

  Breast cancer research : BCR 20120101

• The relative bioavailability study and fasting and fed states pharmacokinetics of bicalutamide 50-mg tablets in healthy Chinese volunteers.

  Arzneimittel-Forschung 20120101

• ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.

  Neoplasia (New York, N.Y.) 20120101

• Photosensitive drug eruption induced by bicalutamide within the UVB action spectrum.

  European journal of dermatology : EJD 20120101

• Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening.

  PloS one 20120101

• Successful Treatment of Advanced Metastatic Prostate Cancer following Chemotherapy Based on Molecular Profiling.

  Case reports in oncology 20120101

• A study of plasma bicalutamide concentrations in hemodialysis patients.

  Urologia internationalis 20120101

• [Clinico-pathological conference report: sudden deterioration of general condition, hypokalemia and diabetes in an elderly man].

  Duodecim; laaketieteellinen aikakauskirja 20120101

• Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.

  International journal of clinical oncology 20111201

• Interstitial pneumonitis induced by bicalutamide given for prostate cancer.

  International journal of clinical oncology 20111201

• Circadian rhythm of hot flashes and activity levels among prostate cancer patients on androgen deprivation therapy.

  The aging male : the official journal of the International Society for the Study of the Aging Male 20111201

• Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models.

  Endocrinology 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Liquid antisolvent precipitation process for solubility modulation of bicalutamide.

  Acta pharmaceutica (Zagreb, Croatia) 20111201

• Modulation of the tumor cell death pathway by androgen receptor in response to cytotoxic stimuli.

  Journal of cellular physiology 20111101

• Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study.

  European journal of nuclear medicine and molecular imaging 20111101

• Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.

  Cancer science 20111101

• Tetrahydroquinolines as a novel series of nonsteroidal selective androgen receptor modulators: structural requirements for better physicochemical and biological properties.

  Bioorganic & medicinal chemistry letters 20111101

• Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening.

  Journal of medicinal chemistry 20110922

• Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines.

  The Prostate 20110915

• Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.

  The Prostate 20110901

• Hunterian Lecture. Characterisation of human prostate epithelial progenitor differentiation in response to androgens.

  Annals of the Royal College of Surgeons of England 20110901

• Targeting androgen receptor in estrogen receptor-negative breast cancer.

  Cancer cell 20110712

• Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI.

  International journal of radiation oncology, biology, physics 20110701

• Preliminary study with bicalutamide in heterosexual and homosexual patients with prostate cancer: a possible implication of androgens in male homosexual arousal.

  BJU international 20110701

• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  The Journal of clinical investigation 20110701

• Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets.

  Journal of medicinal chemistry 20110609

• Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer.

  BJU international 20110601

• Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer.

  BJU international 20110601

• Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110601

• Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines.

  International journal of oncology 20110601

• [Results of 125-iodine seed implant with preplanning system in 250 patients with prostate cancer].

  Actas urologicas espanolas 20110601

• [Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer : a single center experience].

  Hinyokika kiyo. Acta urologica Japonica 20110601

• Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110520

• Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer.

  Biochemistry 20110517

• The antiandrogenic effect of finasteride against a mutant androgen receptor.

  Cancer biology & therapy 20110515

• Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.

  International journal of radiation oncology, biology, physics 20110501

• Comment on 'Androgen-hypersensitive preclinical model of prostate cancer' by Kawata et al.

  The Prostate 20110501

• Androgen stimulates endothelial cell proliferation via an androgen receptor/VEGF/cyclin A-mediated mechanism.

  American journal of physiology. Heart and circulatory physiology 20110401

• Testosterone, not 5α-dihydrotestosterone, stimulates LRH-1 leading to FSH-independent expression of Cyp19 and P450scc in granulosa cells.

  Molecular endocrinology (Baltimore, Md.) 20110401

• Prostate adenocarcinoma with orbital metastasis in an HIV+ man.

  The Canadian journal of urology 20110401

• Influence of short polyglutamine tracts and p160 coactivators on the transactivation of the androgen receptor.

  Cancer biotherapy & radiopharmaceuticals 20110401

• Monte Carlo studies of drug nucleation 1: formation of crystalline clusters of bicalutamide in water.

  The journal of physical chemistry. B 20110331

• Design and synthesis of tricyclic tetrahydroquinolines as a new series of nonsteroidal selective androgen receptor modulators (SARMs).

  Bioorganic & medicinal chemistry letters 20110315

• Cell-cycle regulators cdk2ap1 and bicalutamide suppress malignant biological interactions between prostate cancer and bone cells.

  The Prostate 20110301

• Dehydroepiandrosterone fatty acyl esters in high density lipoprotein: interaction with human vascular endothelial cells and vascular responses ex vivo.

  Steroids 20110301

• Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.

  International journal of oncology 20110301

• Formation of bicalutamide nanodispersion for dissolution rate enhancement.

  International journal of pharmaceutics 20110214

• Depression related to (neo)adjuvant hormonal therapy for prostate cancer.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20110201

• Arylpiperazines for management of benign prostatic hyperplasia: design, synthesis, quantitative structure-activity relationships, and pharmacokinetic studies.

  Journal of medicinal chemistry 20110113

• Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells.

  Molecular and cellular endocrinology 20110101

• Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness.

  Cancer science 20110101

• Daily phosphodiesterase type 5 inhibitor therapy as rescue for recurrent ischemic priapism after failed androgen ablation.

  Journal of andrology 20110101

• [Disseminated carcinomatosis of the bone marrow in two patients with prostate cancer].

  Nihon Hinyokika Gakkai zasshi. The japanese journal of urology 20110101

• Androgen receptor antagonists and anti-prostate cancer activities of some synthesized steroidal candidates.

  Chemical & pharmaceutical bulletin 20110101

• [Impact of neoadjuvant hormonal therapy on the permanent ¹²⁵I-seed brachytherapy for localized high-risk prostate cancer].

  Zhonghua yi xue za zhi 20101228

• Preferential induction of G1 arrest in androgen-responsive human prostate cancer cells by androgen receptor signaling antagonists DL3 and antiandrogen bicalutamide.

  Cancer letters 20101208

• Interaction between AR signalling and CRKL bypasses casodex inhibition in prostate cancer.

  Cellular signalling 20101201

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer.

  Bioorganic & medicinal chemistry 20101201

• Relative bioavailability and tolerability of two formulations of bicalutamide 50-mg tablets: a randomized-sequence, open-label, two-period crossover study in healthy Korean male subjects.

  Clinical therapeutics 20101201

• Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.

  Human molecular genetics 20101115

• Novel selective anti-androgens with a diphenylpentane skeleton.

  Bioorganic & medicinal chemistry letters 20101115

• An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy.

  The Journal of biological chemistry 20101112

• Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.

  Urology 20101101

• Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience.

  International journal of urology : official journal of the Japanese Urological Association 20101101

• No long-term effects of hormonal therapy preceding brachytherapy on urinary function and health-related quality of life among prostate cancer patients.

  Urology 20101101

• The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.

  Oncology reports 20101101

• Developments in nonsteroidal antiandrogens targeting the androgen receptor.

  ChemMedChem 20101004

• Age disrupts androgen receptor-modulated negative feedback in the gonadal axis in healthy men.

  American journal of physiology. Endocrinology and metabolism 20101001

• Inter-related in vitro effects of androgens, fatty acids and oxidative stress in prostate cancer: a mechanistic model supporting prevention strategies.

  International journal of oncology 20101001

• Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival.

  Anticancer research 20101001

• Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT).

  Journal of pediatric endocrinology & metabolism : JPEM 20101001

• Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.

  British journal of cancer 20100928

• A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer.

  International journal of radiation oncology, biology, physics 20100901

• Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer.

  Clinical chemistry 20100901

• Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre.

  Asian journal of andrology 20100901

• Bicalutamide and third-generation aromatase inhibitors in testotoxicosis.

  Pediatrics 20100901

• 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.

  The Prostate 20100801

• Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists.

  Bioorganic & medicinal chemistry letters 20100801

• AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.

  Journal of cellular biochemistry 20100801

• Is prophylactic breast radiotherapy necessary in all patients with prostate cancer and gynecomastia and/or breast pain?

  The Journal of urology 20100801

• Androgen blockade for the treatment of high-flow priapism.

  The journal of sexual medicine 20100701

• Telomerase as an important target of androgen signaling blockade for prostate cancer treatment.

  Molecular cancer therapeutics 20100701

• Management of thrombotic thrombocytopenic purpura in metastatic prostate cancer with only endocrine therapy.

  Annals of the Academy of Medicine, Singapore 20100701

• Comparative study of new shell-type, sub-2 micron fully porous and monolith stationary phases, focusing on mass-transfer resistance.

  Journal of chromatography. A 20100604

• Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity.

  The Prostate 20100515

• Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.

  Urology 20100501

• Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists.

  Bioorganic & medicinal chemistry 20100501

• Editorial comment.

  Urology 20100501

• Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC).

  Journal of medicinal chemistry 20100408

• Androgen receptor interacts with telomeric proteins in prostate cancer cells.

  The Journal of biological chemistry 20100402

• Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.

  The Prostate 20100401

• Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer.

  BJU international 20100401

• 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.

  Endocrinology 20100401

• Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.

  BJU international 20100401

• Androgens induce oxidative stress and radiation resistance in prostate cancer cells though NADPH oxidase.

  Prostate cancer and prostatic diseases 20100301

• Subjective and objective measures of late genitourinary morbidity following hypofractionated radiotherapy in men with prostate cancer.

  Prostate cancer and prostatic diseases 20100301

• Physicochemical characterization of hot melt extruded bicalutamide-polyvinylpyrrolidone solid dispersions.

  Journal of pharmaceutical sciences 20100301

• Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.

  The Prostate 20100301

• Self-assembling methoxypoly(ethylene glycol)-b-poly(carbonate-co-L-lactide) block copolymers for drug delivery.

  Biomaterials 20100301

• REDD1 is a major target of testosterone action in preventing dexamethasone-induced muscle loss.

  Endocrinology 20100301

• The pure anti-androgen bicalutamide inhibits cyclin A expression both in androgen-dependent and -independent cell lines.

  International journal of oncology 20100301

• [Bicalutamide].

  Revue de l'infirmiere 20100301

• Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.

  The Prostate 20100215

• Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H.

  The Journal of biological chemistry 20100212

• An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients.

  European urology 20100201

• A randomized controlled trial of add-back estrogen or placebo on cognition in men with prostate cancer receiving an antiandrogen and a gonadotropin-releasing hormone analog.

  Psychoneuroendocrinology 20100201

• Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A.

  International journal of cancer 20100201

• Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.

  The Prostate 20100201

• Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.

  Clinical breast cancer 20100201

• Comparison of gene expression in LNCaP prostate cancer cells after treatment with bicalutamide or 5-alpha-reductase inhibitors.

  Urologia internationalis 20100101

• Hormonal therapy of prostate cancer.

  Progress in brain research 20100101

• Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer.

  PloS one 20100101

• The effect of concurrent androgen deprivation and 3D conformal radiotherapy on prostate volume and clinical organ doses during treatment for prostate cancer.

  The British journal of radiology 20091201

• Organotypic cultures of prepubertal mouse testes: a method to study androgen action in sertoli cells while preserving their natural environment.

  Biology of reproduction 20091201

• Comparative pharmacokinetic evaluation of two formulations of bicalutamide 50-mg tablets: an open-label, randomized-sequence, single-dose, two-period crossover study in healthy Korean male volunteers.

  Clinical therapeutics 20091201

• Treatment of familial male-limited precocious puberty (testotoxicosis) with anastrozole and bicalutamide in a boy with a novel mutation in the luteinizing hormone receptor.

  Journal of pediatric endocrinology & metabolism : JPEM 20091201

• Disseminated intravascular coagulation secondary to metastatic prostate cancer: case report and review of the literature.

  Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 20091201

• Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate.

  European urology 20091101

• A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results.

  World journal of urology 20091001

• Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy.

  The Journal of urology 20091001

• Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.

  The Canadian journal of urology 20091001

• Design and synthesis of androgen receptor antagonists with bulky side chains for overcoming antiandrogen resistance.

  Journal of medicinal chemistry 20090910

• Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.

  International journal of radiation oncology, biology, physics 20090901

• Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.

  BJU international 20090901

• Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment.

  European journal of nuclear medicine and molecular imaging 20090901

• Micellar delivery of bicalutamide and embelin for treating prostate cancer.

  Pharmaceutical research 20090901

• Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels.

  Urology 20090801

• Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.

  Cancer 20090801

• Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.

  Cancer 20090801

• Androgen deprivation therapy regulation of beta1C integrin expression in prostate cancer.

  Oncology reports 20090801

• [Androgens stimulate the expression of SOCS-3 and inhibits their effect on proliferation and secretion].

  Aktuelle Urologie 20090801

• Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090801

• Interactions of methoxyacetic acid with androgen receptor.

  Toxicology and applied pharmacology 20090715

• Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity.

  Toxicology and applied pharmacology 20090715

• Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts.

  The Journal of steroid biochemistry and molecular biology 20090701

• High performance liquid chromatography method for the pharmacokinetic study of bicalutamide SMEDDS and suspension formulations after oral administration to rats.

  Talanta 20090615

• Duration of androgen suppression in the treatment of prostate cancer.

  The New England journal of medicine 20090611

• Structure determination of chiral sulfoxide in diastereomeric bicalutamide derivatives.

  Chirality 20090601

• Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090520

• Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.

  The Prostate 20090515

• Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.

  Cancer research 20090515

• Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

  Science (New York, N.Y.) 20090508

• Functional AR signaling is evident in an in vitro mouse follicle culture bioassay that encompasses most stages of folliculogenesis.

  Biology of reproduction 20090401

• Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells.

  Cancer research 20090401

• Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies.

  Cancer prevention research (Philadelphia, Pa.) 20090401

• Nanosized bicalutamide and its molecular structure in solvents.

  International journal of pharmaceutics 20090331

• Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.

  Endocrine-related cancer 20090301

• Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.

  Urology 20090301

• Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer.

  Anti-cancer drugs 20090301

• Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic.

  Molecular endocrinology (Baltimore, Md.) 20090301

• Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2.

  Molecular cancer therapeutics 20090301

• Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy.

  International journal of urology : official journal of the Japanese Urological Association 20090301

• [Unreliable survival analysis].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20090226

• [Incorrect about hormone treatment in prostatic cancer].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20090226

• Mechanistic studies on the synthesis of bicalutamide.

  Organic & biomolecular chemistry 20090221

• Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy.

  BJU international 20090201

• Differential mechanisms of bicalutamide-induced apoptosis in prostate cell lines.

  Prostate cancer and prostatic diseases 20090101

• Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.

  Prostate cancer and prostatic diseases 20090101

• A dynamic kinetic asymmetric transformation in the alpha-hydroxylation of racemic malonates and its application to biologically active molecules.

  Angewandte Chemie (International ed. in English) 20090101

• Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer.

  Journal of andrology 20090101

• Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival.

  PloS one 20090101

• Long-term survival and PSA control with radiation and immunotherapy for node positive prostate cancer.

  Clinical & developmental immunology 20090101

• 68Ga-DOTATOC-PET/CT detects neuroendocrine differentiation of prostate cancer metastases.

  Nuklearmedizin. Nuclear medicine 20090101

• Bicalutamide failure in prostate cancer treatment: involvement of Multi Drug Resistance proteins.

  European journal of pharmacology 20081228

• Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes.

  Molecular and cellular endocrinology 20081216

• Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.

  International journal of cancer 20081215

• Skip metastase on the left neck lymph nodes of the prostatic adenocarcinoma with neuroendocrine differentiation and accompanying thyroid micropapillary carcinoma.

  Pathology oncology research : POR 20081201

• Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study.

  Journal of cancer research and clinical oncology 20081201

• Bicalutamide inhibits androgen-mediated adhesion of prostate cancer cells exposed to ionizing radiation.

  The Prostate 20081201

• Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells.

  The Prostate 20081201

• Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.

  The aging male : the official journal of the International Society for the Study of the Aging Male 20081201

• Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.

  Oncogene 20081127

• [Hormone treatment of prostate cancer in Norway].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20081120

• Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines.

  BJU international 20081101

• Molecular basis of agonicity and antagonicity in the androgen receptor studied by molecular dynamics simulations.

  Journal of molecular graphics & modelling 20081101

• Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081020

• A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice.

  Cancer research 20081015

• Increased PAK6 expression in prostate cancer and identification of PAK6 associated proteins.

  The Prostate 20081001

• Nucleation and crystal growth in supersaturated solutions of a model drug.

  Journal of colloid and interface science 20080915

• Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes.

  Carcinogenesis 20080901

• Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.

  The Journal of urology 20080901

• Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.

  Japanese journal of clinical oncology 20080901

• Design and synthesis of carborane-containing androgen receptor (AR) antagonist bearing a pyridine ring.

  Bioorganic & medicinal chemistry 20080901

• Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures.

  Journal of chemical information and modeling 20080901

• Drug-related hepatotoxicity and hepatic failure following combined androgen blockade.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20080901

• Polymorph transitions of bicalutamide: a remarkable example of mechanical activation.

  Journal of pharmaceutical sciences 20080801

• Bicalutamide-associated fulminant hepatotoxicity.

  Pharmacotherapy 20080801

• Development and characterization of bicalutamide-poloxamer F68 solid dispersion systems.

  Die Pharmazie 20080801

• Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.

  The Prostate 20080701

• Cytology of metastatic prostate cancer following orchiectomy and antiandrogen therapy: a diagnostic challenge.

  Diagnostic cytopathology 20080701

• Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).

  Cancer 20080601

• Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones.

  Bioorganic & medicinal chemistry letters 20080601

• Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.

  Carcinogenesis 20080601

• 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells.

  The Prostate 20080515

• Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.

  The Prostate 20080515

• Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy.

  Urology 20080501

• Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.

  Bioorganic & medicinal chemistry letters 20080501

• Discovery and biological characterization of a novel series of androgen receptor modulators.

  British journal of pharmacology 20080501

• Inhibition of apoptosis in prostate cancer cells by androgens is mediated through downregulation of c-Jun N-terminal kinase activation.

  Neoplasia (New York, N.Y.) 20080501

• Screening of 397 chemicals and development of a quantitative structure--activity relationship model for androgen receptor antagonism.

  Chemical research in toxicology 20080401

• Solid-state characterization and dissolution properties of bicalutamide-beta-cyclodextrin inclusion complex.

  Die Pharmazie 20080401

• Maximal androgen blockade for advanced prostate cancer.

  Best practice & research. Clinical endocrinology & metabolism 20080401

• Synthesis and structure-activity relationships of the first ferrocenyl-aryl-hydantoin derivatives of the nonsteroidal antiandrogen nilutamide.

  Journal of medicinal chemistry 20080327

• Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080320

• Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.

  Bioorganic & medicinal chemistry letters 20080315

• The effect of combined androgen blockade on bone turnover and bone mineral density in men with prostate cancer.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080301

• The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.

  Expert review of anticancer therapy 20080301

• Expression of BNIP3 correlates with hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha and the androgen receptor in prostate cancer and is regulated directly by hypoxia but not androgens in cell lines.

  The Prostate 20080215

• Isolation and characterization of process related impurities and degradation products of bicalutamide and development of RP-HPLC method for impurity profile study.

  Journal of pharmaceutical and biomedical analysis 20080213

• Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy.

  Psycho-oncology 20080201

• Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer.

  Urology 20080201

• Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.

  Prostate cancer and prostatic diseases 20080101

• Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer.

  Clinical endocrinology 20080101

• Downregulation of thymosin beta4 expression by androgen in prostate cancer LNCaP cells.

  Journal of andrology 20080101

• The intracellular and nuclear-targeted delivery of an antiandrogen drug by carrier peptides.

  Biopolymers 20080101

• Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.

  Urologic oncology 20080101

• AKT regulates androgen receptor-dependent growth and PSA expression in prostate cancer.

  Advances in experimental medicine and biology 20080101

• Adjuvant hormonal treatment - the bicalutamide early prostate cancer program.

  Frontiers of radiation therapy and oncology 20080101

• Quantum dots-based multiplexed immunohistochemistry of protein expression in human prostate cancer cells.

  European journal of histochemistry : EJH 20080101

• Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.

  The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society 20080101

• Androgen receptor functional analyses by high throughput imaging: determination of ligand, cell cycle, and mutation-specific effects.

  PloS one 20080101

• A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.

  Journal of hematology & oncology 20080101

• Spectrophotometric estimation of bicalutamide in tablets.

  Indian journal of pharmaceutical sciences 20080101

• Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer.

  Oncogene 20071206

• A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission.

  Cancer 20071201

• Treatment of bicalutamide-induced breast events.

  Expert review of anticancer therapy 20071201

• A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone.

  Neoplasia (New York, N.Y.) 20071201

• The efficacy of neoadjuvant androgen deprivation therapy as a prostate volume reduction before brachytherapy for clinically localized prostate cancer.

  Acta medica Okayama 20071201

• Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients.

  Oncology reports 20071101

• [Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy].

  Archivos de la Sociedad Espanola de Oftalmologia 20071101

• Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists.

  Bioorganic & medicinal chemistry letters 20071015

• Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.

  The Journal of urology 20071001

• Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.

  Japanese journal of clinical oncology 20071001

• Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer.

  Urology 20071001

• Androgen receptor-mediated repression of novel target genes.

  The Prostate 20070915

• PC-1/PrLZ contributes to malignant progression in prostate cancer.

  Cancer research 20070915

• A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells.

  Oncogene 20070906

• The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population.

  Journal of cellular physiology 20070901

• In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.

  The Prostate 20070901

• Androgen-dependent regulation of medium and long chain fatty acids uptake in prostate cancer.

  The Prostate 20070901

• Oriental herbs as a source of novel anti-androgen and prostate cancer chemopreventive agents.

  Acta pharmacologica Sinica 20070901

• Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.

  Nature clinical practice. Oncology 20070901

• Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.

  Cancer research 20070901

• Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.

  Urology 20070901

• [Solitary peritoneal carcinomatosis in prostate cancer].

  Aktuelle Urologie 20070901

• Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer.

  Endocrine-related cancer 20070901

• Complete remission of metastatic carcinoma of the prostate with bicalutamide withdrawal.

  Clinical genitourinary cancer 20070901

• Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells.

  The Prostate 20070801

• Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide.

  The Prostate 20070801

• Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs.

  Proceedings of the National Academy of Sciences of the United States of America 20070717

• Bicalutamide-induced gynaecomastia: do we have the answer?

  European urology 20070701

• Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.

  European urology 20070701

• Editorial comment on: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.

  European urology 20070701

• Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia.

  The Prostate 20070701

• Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response.

  Cancer research 20070701

• A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells.

  Molecular cancer therapeutics 20070701

• [Locally advanced prostate cancer: definition, prognosis and treatment].

  Bulletin du cancer 20070701

• Labeling and identification of LNCaP cell surface proteins: a pilot study.

  The Prostate 20070615

• Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.

  The Prostate 20070601

• Androgen regulation of aldehyde dehydrogenase 1A3 (ALDH1A3) in the androgen-responsive human prostate cancer cell line LNCaP.

  Experimental biology and medicine (Maywood, N.J.) 20070601

• Epigallocatechin-3-gallate and bicalutamide cause growth arrest and apoptosis in NRP-152 and NRP-154 prostate epithelial cells.

  International journal of urology : official journal of the Japanese Urological Association 20070601

• [Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20070601

• Prostate cancer tissue is masked by bicalutamide: a case report.

  European journal of medical research 20070529

• Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells.

  The Prostate 20070515

• Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression.

  The Prostate 20070501

• Cushing syndrome associated with prostatic tumor adrenocorticotropic hormone (ACTH) expression after maximal androgen blockade therapy.

  International journal of urology : official journal of the Japanese Urological Association 20070501

• Circumventing anti-androgen resistance by molecular design.

  Journal of the American Chemical Society 20070404

• Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months.

  Journal of clinical pathology 20070401

• EZH2 promotes proliferation and invasiveness of prostate cancer cells.

  The Prostate 20070401

• RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery).

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20070401

• Nuclear and membrane receptor-mediated signalling pathways modulate polyamine biosynthesis and interconversion.

  Biochemical Society transactions 20070401

• Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.

  Bioorganic & medicinal chemistry letters 20070315

• Synthesis and biological evaluation of [18F]bicalutamide, 4-[76Br]bromobicalutamide, and 4-[76Br]bromo-thiobicalutamide as non-steroidal androgens for prostate cancer imaging.

  Journal of medicinal chemistry 20070308

• Ligand-specific dynamics of the androgen receptor at its response element in living cells.

  Molecular and cellular biology 20070301

• Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.

  Asian journal of andrology 20070301

• Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.

  International journal of urology : official journal of the Japanese Urological Association 20070301

• Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.

  International journal of urology : official journal of the Japanese Urological Association 20070301

• 2-(2,2,2-Trifluoroethyl)-5,6-dichlorobenzimidazole derivatives as potent androgen receptor antagonists.

  Bioorganic & medicinal chemistry letters 20070215

• Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).

  The Prostate 20070201

• A role for neurotensin in bicalutamide resistant prostate cancer cells.

  The Prostate 20070201

• Synthesis and SAR of potent and selective androgen receptor antagonists: 5,6-Dichloro-benzimidazole derivatives.

  Bioorganic & medicinal chemistry letters 20070201

• The role of tamoxifen in reducing bicalutamide-induced gynaecomastia and breast pain.

  BJU international 20070201

• [Giant prostate carcinoma treated effectively with endocrine therapy: case report].

  Hinyokika kiyo. Acta urologica Japonica 20070201

• [Gynecomastia as a complication of hormonotherapy for prostate cancer: effect of prophylactic breast irradiation].

  Harefuah 20070201

• Differential regulation of clusterin and its isoforms by androgens in prostate cells.

  The Journal of biological chemistry 20070126

• [Hormonal treatment of cancer of the prostate: review and present status].

  Deutsche medizinische Wochenschrift (1946) 20070126

• The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.

  Biochemistry 20070123

• Conformational polymorphism in bicalutamide.

  International journal of pharmaceutics 20070110

• Dual androgen-response elements mediate androgen regulation of MMP-2 expression in prostate cancer cells.

  Asian journal of andrology 20070101

• Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships.

  Bioorganic & medicinal chemistry 20070101

• The discovery of a potent orally efficacious indole androgen receptor antagonist through in vivo screening.

  Bioorganic & medicinal chemistry letters 20070101

• Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up.

  Prostate cancer and prostatic diseases 20070101

• Evaluation of an in vitro model of androgen ablation and identification of the androgen responsive proteome in LNCaP cells.

  Proteomics 20070101

• Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients.

  Prostate cancer and prostatic diseases 20070101

• Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.

  Molecular cancer therapeutics 20070101

• Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.

  BJU international 20070101

• Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer.

  Drugs & aging 20070101

• Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy.

  Neoplasia (New York, N.Y.) 20070101

• Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.

  Scandinavian journal of urology and nephrology 20070101

• Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.

  Cancer 20061201

• A randomized phase III study of neoadjuvant hormonal therapy in patients with localized prostate cancer.

  Clinical genitourinary cancer 20061201

• [Early prostate cancer 2005. New 2005 data].

  Annales d'urologie 20061201

• [Management of gynecomastia induced by bicalutamide].

  Annales d'urologie 20061201

• Synthesis and SAR of novel hydantoin derivatives as selective androgen receptor modulators.

  Bioorganic & medicinal chemistry letters 20061115

• A bioisosteric approach to the discovery of indole carbinol androgen receptor ligands.

  Bioorganic & medicinal chemistry letters 20061101

• Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens.

  Cancer research 20061101

• [Prostate small cell carcinoma: report of two cases that differed in treatment responsiveness].

  Hinyokika kiyo. Acta urologica Japonica 20061101

• Androgen induction of prostate cancer cell invasion is mediated by ezrin.

  The Journal of biological chemistry 20061006

• Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model.

  The Prostate 20061001

• An improved and validated LC method for resolution of bicalutamide enantiomers using amylose tris-(3,5-dimethylphenylcarbamate) as a chiral stationary phase.

  Journal of pharmaceutical and biomedical analysis 20060926

• Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.

  BJU international 20060901

• Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole.

  The Journal of pediatrics 20060901

• Characteristics of bicalutamide solid dispersions and improvement of the dissolution.

  Drug development and industrial pharmacy 20060901

• Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.

  International journal of urology : official journal of the Japanese Urological Association 20060901

• Distinct regulation by steroids of messenger RNAs for FSHR and CYP19A1 in bovine granulosa cells.

  Biology of reproduction 20060801

• The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.

  The Journal of urology 20060801

• Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells.

  The American journal of pathology 20060801

• The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.

  Journal of cancer research and clinical oncology 20060801

• Hot flashes.

  Clinical journal of oncology nursing 20060801

• Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility.

  Journal of cellular biochemistry 20060701

• Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells.

  The Prostate 20060701

• Digitate dermatosis responding to bicalutamide therapy.

  Clinical and experimental dermatology 20060701

• Are bone scans necessary in men with low prostate specific antigen levels following localized therapy?

  The Journal of urology 20060701

• The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup.

  The Journal of urology 20060701

• Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth.

  The Journal of urology 20060701

• Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg.

  BJU international 20060701

• Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy.

  Urology 20060701

• Preliminary results of bicalutamide monotherapy on biochemical failure of localized prostate cancer.

  Journal of the National Medical Association 20060701

• [8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer].

  Nihon Hinyokika Gakkai zasshi. The japanese journal of urology 20060701

• Treatment of bicalutamide-induced gynecomastia with breast-reduction surgery in prostate cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060620

• Discovery of indole-containing tetracycles as a new scaffold for androgen receptor ligands.

  Bioorganic & medicinal chemistry letters 20060615

• GREB1 is a novel androgen-regulated gene required for prostate cancer growth.

  The Prostate 20060601

• Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.

  BJU international 20060601

• DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells.

  American journal of physiology. Endocrinology and metabolism 20060501

• Combined androgen blockade: an update.

  The Urologic clinics of North America 20060501

• Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?

  Urology 20060501

• Differentially expressed genes in the prostate cancer cell line LNCaP after exposure to androgen and anti-androgen.

  Cancer genetics and cytogenetics 20060415

• Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system.

  Pharmacoepidemiology and drug safety 20060401

• The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer.

  The Journal of urology 20060401

• New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.

  International journal of clinical practice 20060401

• Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.

  Hinyokika kiyo. Acta urologica Japonica 20060401

• Marked sexual dimorphism of lacrimal gland peroxidase in hamster: repression by androgens and estrogens.

  Biochemical and biophysical research communications 20060324

• Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization.

  Molecular endocrinology (Baltimore, Md.) 20060301

• The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide.

  The Prostate 20060301

• Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme.

  BJU international 20060301

• The third analysis of the bicalutamide Early Prostate Cancer programme.

  BJU international 20060301

• Managing locally advanced prostate cancer: a urologist's and a patient's perspective.

  Anti-cancer drugs 20060301

• [13th European Congress of Medical Oncology. Prevention of uterine cancer, adjuvant treatment of early prostate cancer and the promises of nanotechnology].

  Revue medicale suisse 20060208

• Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells.

  The Journal of clinical endocrinology and metabolism 20060201

• Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.

  BJU international 20060201

• [A case of prostatic cancer discovered from lung metastatic lesions].

  Hinyokika kiyo. Acta urologica Japonica 20060201

• (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.

  Journal of medicinal chemistry 20060126

• Side-effects of treatments for locally advanced prostate cancer.

  BJU international 20060101

• Persistence of prostatic intraepithelial neoplasia after effective chemoprevention of microscopic prostate cancer with antiandrogen in a rat model.

  The Journal of urology 20060101

• Screening for metabolically stable aryl-propionamide-derived selective androgen receptor modulators for doping control purposes.

  Rapid communications in mass spectrometry : RCM 20060101

• [Transcriptional regulation of placental transforming growth factor-beta by calcitriol in prostate cancer cells is androgen-independent].

  Molekuliarnaia biologiia 20060101

• Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.

  Anticancer research 20060101

• Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression.

  Prostate cancer and prostatic diseases 20060101

• Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.

  Drugs 20060101

• Pharmacokinetics of two novel bicalutamide formulations in healthy male volunteers.

  Pharmacology 20060101

• Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients.

  The International journal of biological markers 20060101

• The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.

  Urologia internationalis 20060101

• Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.

  Urologia internationalis 20060101

• Estrogen-receptor-alpha-positive extramammary Paget's disease treated with hormonal therapy.

  Dermatology (Basel, Switzerland) 20060101

• Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years.

  Scandinavian journal of urology and nephrology 20060101

• High-performance liquid chromatographic enantioseparation of bicalutamide and its related compounds.

  Journal of chromatography. A 20051209

• Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.

  The Prostate 20051201

• Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.

  The Prostate 20051201

• Secretoglobin 2A1 is under selective androgen control mediated by a peculiar binding site for Sp family transcription factors.

  Molecular endocrinology (Baltimore, Md.) 20051201

• Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.

  The Journal of urology 20051201

• Co-activator and co-repressor interplay on the human androgen receptor.

  Andrologia 20051201

• Testotoxicosis: current viewpoint.

  Pediatric endocrinology reviews : PER 20051201

• Direct agonist/antagonist functions of dehydroepiandrosterone.

  Endocrinology 20051101

• Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells.

  The Prostate 20051101

• The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.

  BJU international 20051101

• Estrogenic induction of spermatogenesis in the hypogonadal (hpg) mouse: role of androgens.

  Reproduction (Cambridge, England) 20051101

• Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.

  Cancer research 20051101

• Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.

  Cancer chemotherapy and pharmacology 20051001

• A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.

  BJU international 20051001

• Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.

  BJU international 20051001

• Prostate cancer presenting with fever and rigors.

  Internal medicine journal 20051001

• [Usefulness and positioning of MAB therapy for prostate cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20051001

• Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?

  Urology 20051001

• Insulin resistance as an adverse effect of leuprolide and bicalutamide treatment.

  The journals of gerontology. Series A, Biological sciences and medical sciences 20051001

• Antiandrogens prevent stable DNA-binding of the androgen receptor.

  Journal of cell science 20050915

• Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.

  The Prostate 20050901

• Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.

  Oncology reports 20050901

• Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer.

  Anti-cancer drugs 20050901

• Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.

  BJU international 20050901

• Late radiotherapy toxicity after prostate cancer treatment: influence of hormonal therapy.

  Urology 20050901

• Radiotherapeutic prophylaxis of gynecomastia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820

• Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S phase.

  Journal of cellular physiology 20050801

• Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression.

  The Journal of pathology 20050801

• The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.

  The Journal of urology 20050801

• The experiences of men receiving androgen deprivation treatment for prostate cancer: a qualitative study.

  The Canadian journal of urology 20050801

• The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.

  Proceedings of the National Academy of Sciences of the United States of America 20050712

• Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.

  International journal of cancer 20050701

• Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20050701

• The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20050601

• An interdisciplinary approach to treating prostate cancer.

  Urology 20050601

• Treating the biochemical recurrence of prostate cancer after definitive primary therapy.

  Clinical prostate cancer 20050601

• Locally advanced prostate cancer treated with radiotherapy and androgen deprivation.

  Nature clinical practice. Urology 20050601

• 5alpha-dihydrotestosterone inhibits 1alpha,25-dihydroxyvitamin D3-induced expression of CYP24 in human prostate cancer cells.

  The Prostate 20050515

• Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells.

  The Prostate 20050501

• Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer.

  Current opinion in urology 20050501

• Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.

  European urology 20050501

• Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer.

  European urology 20050501

• Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial.

  The Lancet. Oncology 20050501

• [Reevaluation of MAB therapy and progress of endocrine therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050501

• Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.

  Journal of medicinal chemistry 20050421

• A case of male breast cancer in association with bicalutamide-induced gynaecomastia.

  Breast (Edinburgh, Scotland) 20050401

• Reversibility of androgen deprivation therapy in patients with prostate cancer.

  The Journal of urology 20050301

• Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.

  Cancer research 20050301

• Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.

  Endocrine-related cancer 20050301

• Successful recovery from interstitial pneumonitis, induced by bicalutamide and leuprorelin acetate given as treatment for prostate cancer.

  Hinyokika kiyo. Acta urologica Japonica 20050301

• Combined androgen blockade: the case for bicalutamide.

  Clinical prostate cancer 20050301

• Three-dimensional structure-activity relationships of nonsteroidal ligands in complex with androgen receptor ligand-binding domain.

  Journal of medicinal chemistry 20050224

• Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050201

• Comparison of microvessel densities in rat prostate tissues treated with finasteride, bicalutamide and surgical castration: a preliminary study.

  International journal of urology : official journal of the Japanese Urological Association 20050201

• Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.

  Bioorganic & medicinal chemistry letters 20050117

• Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.

  Bioorganic & medicinal chemistry letters 20050117

• Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines.

  The Journal of pharmacy and pharmacology 20050101

• Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus.

  Urology 20050101

• [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050101

• Randomized controlled trial to evaluate radiotherapy +/- endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401.

  Japanese journal of clinical oncology 20050101

• Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole.

  Prostate cancer and prostatic diseases 20050101

• Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.

  Prostate cancer and prostatic diseases 20050101

• Prolonged response to nilutamide in a patient with stage D0.5 prostate cancer who previously failed androgen deprivation therapy.

  American journal of therapeutics 20050101

• Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model.

  BMC urology 20050101

• Comparative effects of bicalutamide (Casodex) versus orchidectomy on bone mineral density, bone remodelling, and bone biomechanics in healthy rats.

  Urologia internationalis 20050101

• Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme.

  Prostate cancer and prostatic diseases 20050101

• Case study: management of advanced prostate cancer with soft tissue metastases.

  Prostate cancer and prostatic diseases 20050101

• Case study: management of lymph node-positive disease detected at radical prostatectomy.

  Prostate cancer and prostatic diseases 20050101

• Impact of hormone therapy on acute radiotherapy toxicity in the treatment of prostate cancer.

  Prostate cancer and prostatic diseases 20050101

• Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy.

  The International journal of biological markers 20050101

• Proptosis and decreased vision secondary to prostate cancer orbital wall metastasis.

  Anticancer research 20050101

• Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.

  Urologia internationalis 20050101

• 4-OH tamoxifen does not interfere with bicalutamide inhibitory effects on human prostatic cancer cells in vitro.

  Anticancer research 20050101

• Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor.

  Molecular endocrinology (Baltimore, Md.) 20041101

• Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041101

• Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years.

  The Journal of urology 20041101

• Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.

  The Journal of urology 20041101

• The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer.

  The Journal of pathology 20041001

• Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia.

  International journal of radiation oncology, biology, physics 20041001

• Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.

  Cancer research 20041001

• Effects of testosterone, dihydrotestosterone, and 17beta-estradiol on human ovarian tissue survival in culture.

  Fertility and sterility 20041001

• Bicalutamide 150 mg: practical prescribing in patients with early prostate cancer.

  BJU international 20041001

• Unexpected response of hormone-refractory prostate cancer to treatment with an antileukemic chemotherapy regimen.

  Urology 20041001

• Monotherapy in advanced prostate cancer: an overview.

  Experimental oncology 20040901

• Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy.

  The Journal of urology 20040801

• Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.

  The Journal of urology 20040801

• The 3rd Conference on Asian Trends in Prostate Cancer Hormone Therapy.

  Gan to kagaku ryoho. Cancer & chemotherapy 20040801

• Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.

  The Journal of steroid biochemistry and molecular biology 20040801

• A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor.

  Journal of medicinal chemistry 20040715

• Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040701

• Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer.

  The Journal of urology 20040601

• Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer.

  Oncology reports 20040601

• The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review.

  Oncology reports 20040601

• Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040601

• Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells.

  Journal of molecular endocrinology 20040601

• Synergistic induction of the nicotinamide adenine dinucleotide-linked 15-hydroxyprostaglandin dehydrogenase by an androgen and interleukin-6 or forskolin in human prostate cancer cells.

  Endocrinology 20040501

• Re: See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T. Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostatic cancer. Eur Urol 2003;44:512-8.

  European urology 20040501

• Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.

  Urology 20040501

• Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells.

  Oncogene 20040422

• Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells.

  The Journal of biological chemistry 20040409

• Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.

  Urology 20040301

• An evaluation of bicalutamide in the treatment of prostate cancer.

  Clinical prostate cancer 20040301

• Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.

  The Journal of urology 20040201

• Bicalutamide (Casodex) in the treatment of prostate cancer.

  Expert review of anticancer therapy 20040201

• [A case of seminal vesicle cyst due to the obstruction of the ejaculatory duct: possible association with prostate cancer].

  Hinyokika kiyo. Acta urologica Japonica 20040201

• Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERT.

  Cancer 20040115

• Prognosis of stage pT0 after prolonged neoadjuvant endocrine therapy of prostate cancer: a matched-pair analysis.

  European urology 20040101

• Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.

  Urologia internationalis 20040101

• Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients.

  Japanese journal of clinical oncology 20040101

• High-dose radiotherapy plus prolonged hormone therapy in CT2-3 prostatic carcinoma: is it useful?

  Tumori 20040101

• Cost-effectiveness analysis of bicalutamide (Casodex) for adjuvant treatment of early prostate cancer.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20040101

• [Neoadjuvant hormone therapy with casodex in a dose 150 mg prior to radical prostatectomy in patients with prostatic cancer].

  Urologiia (Moscow, Russia : 1999) 20040101

• Bicalutamide: clinical pharmacokinetics and metabolism.

  Clinical pharmacokinetics 20040101

• Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance.

  Hormone research 20040101

• Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines.

  Neoplasma 20040101

• Which patients with prostate cancer are actually candidates for hormone therapy?

  International braz j urol : official journal of the Brazilian Society of Urology 20040101

• Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.

  Urology 20031229

• Nucleophilic aromatic substitution of methacrylamide anion and its application to the synthesis of the anticancer drug bicalutamide.

  The Journal of organic chemistry 20031226

• Antiandrogenic activities of diesel exhaust particle extracts in PC3/AR human prostate carcinoma cells.

  Toxicological sciences : an official journal of the Society of Toxicology 20031201

• Bicalutamide monotherapy for early stage prostate cancer: an update.

  The Journal of urology 20031201

• Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway.

  Endocrinology 20031101

• Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines.

  The Journal of urology 20031101

• Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study.

  European urology 20031101

• Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer.

  European urology 20031101

• Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer.

  Cancer research 20031101

• Hormonal and morphologic evaluation of the effects of antiandrogens on the blood supply of the rat prostate.

  Urology 20031101

• Interstitial pneumonitis induced by bicalutamide and leuprorelin acetate for prostate cancer.

  International journal of urology : official journal of the Japanese Urological Association 20031101

• Isolation and identification of L-dopa decarboxylase as a protein that binds to and enhances transcriptional activity of the androgen receptor using the repressed transactivator yeast two-hybrid system.

  The Biochemical journal 20031015

• The role of anti-androgen monotherapy in the treatment of prostate cancer.

  BJU international 20031001

• [Comparative study of the effect of complete prolonged neoadjuvant hormonal blockade versus standard hormonal blockade].

  Actas urologicas espanolas 20031001

• Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.

  Cancer research 20030901

• Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20030901

• The clinical rationale for immediate androgen deprivation without estrogen deprivation.

  Clinical prostate cancer 20030901

• Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis.

  Oncogene 20030828

• A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030801

• Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells.

  Molecular carcinogenesis 20030801

• Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer.

  American journal of clinical oncology 20030801

• UV filters with antagonistic action at androgen receptors in the MDA-kb2 cell transcriptional-activation assay.

  Toxicological sciences : an official journal of the Society of Toxicology 20030701

• Antiandrogen-induced cell death in LNCaP human prostate cancer cells.

  Cell death and differentiation 20030701

• Plant-derived 3,3'-Diindolylmethane is a strong androgen antagonist in human prostate cancer cells.

  The Journal of biological chemistry 20030606

• Management of treatment-related osteoporosis in men with prostate cancer.

  Cancer treatment reviews 20030601

• Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity.

  American journal of clinical oncology 20030601

• [Effect of bicalutamide 150 mg, after 3 years of median follow-up, in non-metastatic prostatic cancer].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20030601

• The non-steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study.

  World journal of urology 20030501

• [A case of locally advanced prostate cancer with low serum testosterone associated with intake of an androgenic medicine].

  Nihon Hinyokika Gakkai zasshi. The japanese journal of urology 20030501

• Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells.

  The Journal of steroid biochemistry and molecular biology 20030501

• Bioassay of steroid hormone agonist and antagonist activities of anti-androgens on mammary gland, seminal vesicles and spleen of male mice.

  Journal of veterinary medicine. A, Physiology, pathology, clinical medicine 20030501

• Store-operated Ca2+ current in prostate cancer epithelial cells. Role of endogenous Ca2+ transporter type 1.

  The Journal of biological chemistry 20030425

• Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells.

  Cancer research 20030415

• Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells.

  Cancer research 20030415

• Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program.

  BJU international 20030401

• Newer approaches to androgen deprivation therapy in prostate cancer.

  Urology 20030401

• Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy.

  Cancer 20030301

• The role of antiandrogen monotherapy in the treatment of prostate cancer.

  BJU international 20030301

• Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.

  Cancer 20030201

• A longer duration of neo-adjuvant combined androgen blockade prior to radical prostatectomy may lead to lower tumour volume of localised prostate cancer.

  European urology 20030201

• Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor.

  Molecular pharmacology 20030101

• Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma.

  European urology 20030101

• Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

  Cancer research 20030101

• [First line therapy in the treatment of metastatic prostate cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20030101

• Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer.

  Urology 20030101

• Immediate or deferred hormonal therapy?

  Scandinavian journal of urology and nephrology. Supplementum 20030101

• Adjuvant hormonal treatment for prostate cancer: the bicalutamide early prostate cancer program.

  Oncology 20030101

• Biochemical recurrence of prostate cancer.

  Current problems in cancer 20030101

• Elevated E-cadherin and alpha/beta-catenin expression after androgen deprivation therapy in prostate adenocarcinoma.

  Pathology, research and practice 20030101

• Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex.

  The Journal of biological chemistry 20021213

• Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20021201

• [Antiandrogen in prostate cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20021201

• [Total androgen blockade].

  Nihon rinsho. Japanese journal of clinical medicine 20021201

• Induction of invasive phenotype by Casodex in hormone-sensitive prostate cancer cells.

  The Journal of steroid biochemistry and molecular biology 20021201

• Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial.

  European urology 20021101

• Unusual anti-angiogenic effect of combined hormonal blockade.

  The Journal of urology 20021001

• Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect.

  Annals of internal medicine 20021001

• An evaluation of bicalutamide in the treatment of prostate cancer.

  Expert opinion on pharmacotherapy 20020901

• Emerging role of adjuvant hormonal therapy.

  Urology 20020901

• Antiandrogen monotherapy: indications and results.

  Urology 20020901

• Osteoporosis during androgen deprivation therapy for prostate cancer.

  Urology 20020901

• Secondary hormonal therapies in the treatment of prostate cancer.

  Urology 20020901

• Androgen receptor as a target in androgen-independent prostate cancer.

  Urology 20020901

• A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6.

  European urology 20020901

• Tolerability assessment of maximal androgen blockade with 50 mg daily of bicalutamide and castration in patients with advanced prostate cancer.

  Chang Gung medical journal 20020901

• Highlights from the 97th Annual Meeting of the American Urological Association: Orlando, Florida, May 25-30, 2002.

  Clinical prostate cancer 20020901

• Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.

  The Journal of urology 20020801

• Regulation of FGF8 expression by the androgen receptor in human prostate cancer.

  Oncogene 20020801

• Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor.

  European journal of medicinal chemistry 20020801

• Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor.

  The Journal of biological chemistry 20020719

• Pure antiandrogens disrupt the recruitment of coactivator GRIP1 to colocalize with androgen receptor in nuclei.

  FEBS letters 20020717

• Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer.

  Journal of clinical pathology 20020701

• Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020701

• Stabilization of androgen receptor protein is induced by agonist, not by antagonists.

  Biochemical and biophysical research communications 20020621

• A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer.

  Endocrinology 20020501

• AR possesses an intrinsic hormone-independent transcriptional activity.

  Molecular endocrinology (Baltimore, Md.) 20020501

• Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

  The Journal of biological chemistry 20020419

• A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer.

  The Journal of urology 20020401

• The amino terminus of the human AR is target for corepressor action and antihormone agonism.

  Molecular endocrinology (Baltimore, Md.) 20020401

• [The role of bicalutamide in the treatment of prostate cancer].

  Harefuah 20020401

• Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways.

  The Journal of biological chemistry 20020301

• [Adjuvant treatment of prostatic carcinoma after primary therapy. The 'Early Prostate Cancer' Program].

  Recenti progressi in medicina 20020301

• [Adjuvant hormone therapy in prostatic cancer: after treatment with curative intent. The viewpoint of the urologist].

  Recenti progressi in medicina 20020301

• [Efficacy of bicalutamide in adjuvant treatment of prostatic carcinoma after primary therapy with curative aim. The viewpoint of the surgeon].

  Recenti progressi in medicina 20020301

• Bone alkaline phosphatase serum level predicts the response to antiandrogen withdrawal.

  European urology 20020301

• AIbZIP, a novel bZIP gene located on chromosome 1q21.3 that is highly expressed in prostate tumors and of which the expression is up-regulated by androgens in LNCaP human prostate cancer cells.

  Cancer research 20020201

• Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer.

  International journal of radiation oncology, biology, physics 20020201

• Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients.

  Neuro endocrinology letters 20020201

• New alternative treatment in hirsutism: bicalutamide 25 mg/day.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20020201

• Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer.

  Endocrine journal 20020201

• Role of cadmium in the regulation of AR gene expression and activity.

  Endocrinology 20020101

• Antiandrogens in the treatment of priapism.

  Urology 20020101

• Comparative study of pressure-flow parameters.

  Neurourology and urodynamics 20020101

• Prostate-specific antigen dynamics predict risk of progression in advanced prostate cancer treated with bicalutamide plus castration.

  Urologia internationalis 20020101

• [Monotherapy with casodex at a dose of 150 mg--a new method of hormonal treatment of disseminated prostatic cancer].

  Urologiia (Moscow, Russia : 1999) 20020101

• Bicalutamide: in early-stage prostate cancer.

  Drugs 20020101

• Bicalutamide dose-dependently inhibits proliferation in human prostatic carcinoma cell lines and primary cultures.

  Anticancer research 20020101

• Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.

  Prostate cancer and prostatic diseases 20020101

• Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide.

  Laboratory investigation; a journal of technical methods and pathology 20011201

• Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: identification of divergent growth regulatory pathways.

  The Prostate 20010915

• Prostate cancer in the older man.

  Oncology (Williston Park, N.Y.) 20010901

• Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression.

  Urology 20010801

• Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer.

  Urology 20010801

• [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].

  Hinyokika kiyo. Acta urologica Japonica 20010801

• Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.

  Seminars in oncology 20010801

• Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).

  Urology 20010701

• Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.

  The Prostate 20010615

• Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010601

• New drug for prostate cancer.

  European journal of cancer care 20010601

• Prostate-specific antigen-all that rises is not refractory.

  Urology 20010501

• CaT1 expression correlates with tumor grade in prostate cancer.

  Biochemical and biophysical research communications 20010406

• The effect of bicalutamide on prostate histology.

  The Prostate 20010301

• Long-term exposure of tumor necrosis factor alpha causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells.

  The Prostate 20010301

• Effects of long-term treatment with the anti-androgen bicalutamide on human testis: an ultrastructural and morphometric study.

  Histopathology 20010301

• Cross-talk between steroid-receptor-mediated and cell-membrane-receptor-mediated signalling pathways results in the in vivo modulation of c-Met and ornithine decarboxylase gene expression in mouse kidney.

  The Biochemical journal 20010115

• Treatment of locally advanced prostate cancer--a new role for antiandrogen monotherapy?

  European urology 20010101

• Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function.

  BJU international 20010101

• Levels of alpha 2 macroglobulin can predict bone metastases in prostate cancer.

  Anticancer research 20010101

• Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.

  The oncologist 20010101

• Ultrastructural and quantitative immunohistochemical changes induced by nonsteroid antiandrogens on pituitary gonadotroph population of prepubertal male rats.

  Cells, tissues, organs 20010101

• [Bicalutamide monotherapy of patients with disseminated forms of prostatic cancer].

  Urologiia (Moscow, Russia : 1999) 20010101

• [Changes in prostate-specific antigen in casodex (bicalutamide) monotherapy in a dose 150 mg/day given to patients with locally advanced and/or advanced prostatic cancer].

  Urologiia (Moscow, Russia : 1999) 20010101

• Delaying/reducing the risk of clinical tumour progression after primary curative procedures.

  European urology 20010101

• Neither fibroblast growth factor-1 nor fibroblast growth factor-2 is an androgen receptor coactivator in androgen-resistant prostate cancer.

  Molecular urology 20010101

• [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].

  Urologiia (Moscow, Russia : 1999) 20010101

• Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.

  Neoplasma 20010101

• Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance.

  Drug safety 20001101

• Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.

  Cancer research 20001015

• 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.

  Endocrinology 20000701

• Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins.

  Urology 19991201

• Regulation of GCDFP-15 expression in human mammary cancer cells.

  International journal of molecular medicine 19990801

• Rapid and sensitive reporter gene assays for detection of antiandrogenic and estrogenic effects of environmental chemicals.

  Toxicology and applied pharmacology 19990301

• Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.

  Journal of medicinal chemistry 19980212

• A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats.

  Cancer 19980201

• 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.

  Endocrinology 19970801

• Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters.

  Urology 19970401